Arie Pharmaceuticals

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for patients with open-angle glaucoma and other eye diseases. The company's lead products, Rhopressa and Rocklatan, represent the first new therapeutic class for glaucoma in over 20 years, specifically targeting the trabecular meshwork to improve fluid outflow. Beyond its commercial glaucoma franchise, Aerie has advanced a pipeline of candidates for dry eye disease and retinal diseases such as macular edema. In November 2022, the company was acquired by Alcon for approximately 770 million dollars, integrating its specialized R&D and commercial capabilities into Alcon's global ophthalmology portfolio. Aerie's technology platform is built on its expertise in Rho kinase (ROCK) inhibition and small molecule design tailored for ocular delivery. The company maintains a significant presence in the United States and operates a state-of-the-art manufacturing facility in Athlone, Ireland.